Stryker Co. (NYSE:SYK) Shares Sold by Fundsmith LLP

Fundsmith LLP reduced its stake in Stryker Co. (NYSE:SYK) by 0.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,333,977 shares of the medical technology company’s stock after selling 2,844 shares during the quarter. Stryker makes up approximately 8.2% of Fundsmith LLP’s investment portfolio, making the stock its 3rd largest position. Fundsmith LLP’s holdings in Stryker were worth $1,920,498,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Norges Bank acquired a new stake in Stryker during the fourth quarter worth about $1,710,744,000. Raymond James Financial Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $353,394,000. FMR LLC increased its holdings in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after buying an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock valued at $214,660,000 after acquiring an additional 595,061 shares during the last quarter. Finally, Northern Trust Corp grew its position in Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company’s stock worth $1,298,426,000 after acquiring an additional 420,153 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.4 %

Shares of NYSE:SYK opened at $382.68 on Friday. The company has a market cap of $146.06 billion, a PE ratio of 49.31, a P/E/G ratio of 2.93 and a beta of 0.93. The company’s 50 day moving average is $365.66 and its two-hundred day moving average is $374.20. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $2.50 EPS. Equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker’s dividend payout ratio is presently 45.41%.

Analyst Ratings Changes

A number of equities research analysts have commented on SYK shares. Roth Mkm lifted their target price on Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Argus set a $450.00 target price on shares of Stryker in a research report on Monday, February 3rd. Needham & Company LLC restated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. JPMorgan Chase & Co. boosted their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a report on Monday. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $427.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.